Xspray Pharma’s Nomination Committee for the Annual General Meeting, May 2027

XSPRAYRegulatoriskt pressmeddelande2026-11-10 14:22

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee’s composition for the Annual General Meeting in 2027.

The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 12 May 2026, consists of:

Thomas Eldered, appointed by Flerie AB, Chairman of the Nomination Committee
Johan Gyllenswärd, appointed by Ribbskottet AB
Mattias Klintemar, appointed by The Foundation for Baltic and East European Studies
Johan Wadell, appointed by AP2
Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB

The Nomination Committee shall, before the Annual General Meeting on May 11, 2027, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual Meeting, election of auditors, the determination of fees and matters pertaining thereto.

Shareholders who wish to submit proposals to the Nomination Committee prior to the Annual General Meeting, can do so via e-mail to generalmeeting@xspray.com before March 23, 2027.

For further information about the Nomination Committee, please contact:
Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB
Email: anders.ekblom@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development utilizing its innovative, patent protected HyNap™ technology platform to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology market segment, often with high drug prices. The company’s goal is to become the market leader in improved PKI’s for cancer treatment. Xspray Pharma’s lead drug candidate, Dasynoc® and Nilopki® (an optimized version of Tasigna®) are currently undergoing FDA review. Dasynoc is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose due to a better solubility profile. Its compatibility with proton pump inhibitors (PPIs), which are often co-prescribed to patients with CML and ALL, is a significant advantage. Xspray Pharma is building a robust product portfolio, including Nilopki and XS008-axitinib (an optimized version of Inlyta®) and XS025-cabozantinib (an optimized version of Cabometyx®).

The Xspray Pharma AB-share is trading at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com.